By incorporating appropriate drug(s) into lipid (biobased) nanocarriers, one obtains a combination therapeutic for dementia treatment that targets certain cell-surface scavenger receptors (mainly class B type I, or “SR-BI”) and thereby crosses the blood-brain barrier. The cardiovascular risk factors for dementia trigger widespread inflammation -- which lead to neurodegeneration, gradual cognitive/memory decline, and eventually (late-onset) dementia. Accordingly, one useful strategy to delay dementia could be based upon nanotargeting drug(s), using lipid nanocarriers, toward a major receptor class responsible for inflammation-associated (cytokine-mediated) cell signaling events. At the same time, the immune response and excessive inflammation, commonly observed in the very recent human coronavirus (COVID-19) pandemic, may accelerate the progression of brain inflammatory neurodegeneration—which increases the probability of post-infection memory impairment and accelerating progression of Alzheimer’s disease. Hence, the proposed multitasking combination therapeutic, using a (biobased) lipid nanocarrier, may also display greater effectiveness at different stages of dementia.

通过将适当的一种或多种药物掺入脂质（基于生物的）纳米载体中，可以获得针对痴呆症治疗的联合治疗药物，其靶向某些细胞表面清除剂受体（主要是B类I型或“ SR-BI”），从而跨血-脑屏障。痴呆症的心血管危险因素会引发广泛的炎症-导致神经变性，逐渐的认知/记忆力下降，并最终导致（迟发性）痴呆症。因此，一种延迟痴呆的有用策略可以基于使用脂质纳米载体的纳米靶向药物针对负责炎症相关的（细胞因子介导的）细胞信号转导事件的主要受体类别。同时，在最近的人类冠状病毒（COVID-19）大流行中通常会观察到免疫反应和过度炎症，可能会加速脑炎性神经退行性疾病的发展，从而增加感染后记忆障碍的可能性，并加速阿尔茨海默氏病的发展。因此，使用（基于生物的）脂质纳米载体的所提出的多任务联合治疗剂在痴呆的不同阶段也可能显示出更大的有效性。